Regentis Biomaterials Ltd. (NYSE:RGNT) — Market Cap & Net Worth
Market Cap & Net Worth: Regentis Biomaterials Ltd. (RGNT)
Regentis Biomaterials Ltd. (NYSE:RGNT) has a market capitalization of $13.28 Million ($13.28 Million) as of August 24, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #26432 globally and #5497 in its home market, demonstrating a 10.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regentis Biomaterials Ltd.'s stock price $2.10 by its total outstanding shares 7023921 (7.02 Million). Check today's stock price for Regentis Biomaterials Ltd. for real-time trading data and today's change.
Regentis Biomaterials Ltd. Market Cap History: 2026 to 2026
Regentis Biomaterials Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $14.75 Million to $14.75 Million (0.00% CAGR).
Regentis Biomaterials Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regentis Biomaterials Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check RGNT total equity to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RGNT by Market Capitalization
Companies near Regentis Biomaterials Ltd. in the global market cap rankings as of August 24, 2026. Also see how efficiently does Regentis Biomaterials Ltd. generate cash for how efficiently the company converts equity into cash flow.
Key companies related to Regentis Biomaterials Ltd. by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #179 globally with a market cap of $135.72 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #308 globally with a market cap of $88.35 Billion USD ( €75.57 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #364 globally with a market cap of $78.07 Billion USD ( €66.78 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #544 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #179 | Intuitive Surgical Inc | NASDAQ:ISRG | $135.72 Billion | $378.81 |
| #308 | EssilorLuxottica S. A. | PA:EL | $88.35 Billion | €163.20 |
| #364 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $78.07 Billion | €79.50 |
| #544 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Regentis Biomaterials Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, Regentis Biomaterials Ltd.'s market cap moved from $14.75 Million to $ 14.75 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.75 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Regentis Biomaterials Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.28 Million USD |
| MoneyControl | $13.28 Million USD |
| MarketWatch | $13.28 Million USD |
| marketcap.company | $13.28 Million USD |
| Reuters | $13.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical tr… Read more